medigraphic.com
ISSN 1527-3172 (Electronic)

2009, Number 3

<< Back Next >>

MEDICC Review 2009; 11 (3)

Transforming Cancer Indicators begs bold new strategies from biotechnology

Lage A

Language: English
References: 9
Page: 8-12
PDF size: 501.85 Kb.


ABSTRACT

A national cancer program is essentially a population health initiative that goes beyond satisfying the demand for health services to propose modifying specific objective indicators in a defined population through interventions that have a scientifically grounded probability of success.
In the case of malignant neoplasms, the three “gold standard” indicators are age-adjusted specific mortality, age-adjusted incidence, and average 5- or 10-year survival rates. All other frequently used indicators—such as stage distribution at time of diagnosis, participation in early diagnostic interventions, intensity of public health education efforts, and coverage of chemo- and radiotherapy services, among others—are valid to the extent they are predictors of the three “gold standard” indicators.


REFERENCES

  1. Ernst & Young. Beyond Borders: The Global Biotechnology Report 2007 [monograph on the Internet].OECD; 2007 [cited 2008 Jun]. Available from: http://www.ey.com/Publication/vwLUAssets/beyond_borders2007/$FILE/ BeyondBorders2007.pdf

  2. van Beuzekom B, Arundel A. OECD, 2006. Biotechnology Statistics [monograph on the Internet]. OECD; 2006 [cited 2008 Jun]. Available from: http:// www.oecd.org/dataoecd/51/59/36760212.pdf

  3. Pharmaceutical Manufacturers Association of America, 2008. Biotechnology Medicines 2008 [monograph on the Internet]. PhRMA; 2008 [cited 2009 Apr]. Available from: http://www.phrma.org/images/110308%20biotech%20 2008.pdf

  4. Eisenhauer EA. Response evaluation: beyond RECIST. Ann Oncol. 2007 Jul;18(Suppl 9):ix29-32. Review.

  5. Evenson D. Cuba’s Biotechnology Revolution. MEDICC Review. 2007 Fall;9(1):8-10.

  6. Lage A. Connecting science to population health: the “closed loop” approach. MEDICC Review. 2007 Fall;9(1):48.

  7. Lage A, Pérez R, Fernández LE. Therapeutic Cancer Vaccines: at midway between immunology and pharmacology. Curr Cancer Drug Targets. 2005 Dec;5(8):611-27.

  8. Earle CC, Tsai JS, Gelber RD, Weinstein MC, Neumann PJ, Weeks JC. Effectiveness of Chemotherapy for Advanced Lung Cancer in the Elderly: Instrumental Variable and Propensity Analysis. J Clin Oncol. 2001 Feb 15;19(4):1064-70.

  9. Lage A. Connecting immunology research to public health: Cuban biotechnology. Nat Immunol. 2008 Feb;9(2):109-12.




2020     |     www.medigraphic.com